responses

Investigational combination of first-in-class bispecific antibodies TALVEY (talquetamab) and TECVAYLI (teclistamab) shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease

Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response rate through dual targeting of…

7 months ago

Indian Researchers Call for Balanced and Responsible Research Assessments: Springer Nature Survey Reveals Global Insights

NEW DELHI, June 11, 2025 /PRNewswire/ -- A global survey conducted by Springer Nature reveals that researchers in India are…

7 months ago

Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma

Extended Phase 1b trial follow-up on IMA203 PRAME cell therapy in 33 heavily pretreated patients with metastatic melanoma demonstrates favorable…

7 months ago
Show previous Posts